Found this on the Yahoo board; and article over the weekend mentioned big gorilla Amgen in P2 with obesity drug. If this and the correction are all the bad news for awhile, this may be the bottom on Regn...
Hanging in-
E
This from "Stemlock_2000"....<<<I did a quick calculation of Regeneron's book value before and after the secondary offering and thought I'd post it. Since we only have the Dec. 31 figures available, I based it upon those figures and added the amount received from their public offering of 2,600,000 shares. This will be a bit inaccurate since they?ve burned a little cash since Dec. 31. According to the SEC 8-K, they received $73,502,000 from issueing 2,600,000 shares. This must be offset by the $550,000 commission fee.
At Dec. 31:
Cash & Equivalents: $93,600,000
Shareholder Equity: $136,999,000
Shares outstanding: 31,341,000
Book value: $4.37
After Secondary Offering:
Cash & Equivalents: $93,600,000 + $73,502,000 - $550,000 = $ 166,552,000
Shareholder Equity: $136,999,000 + $73,502,000 - $550,000 = $ 209,951,000
Shares outstanding: 31,341,000 + 2,600,000 = 33,941,000
Book value: $6.18
Recent price: $17.5 April 14, 2000
Price/Book value: 2.82 >>> |
